Drug Profile
Research programme: anti-VEGF therapeutics - Pharmexa
Alternative Names: VEGF AutoVacLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Pharmexa
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2007 Discontinued - Preclinical for Cancer in Denmark (Parenteral)
- 11 Jan 2005 Pharmexa and Epimmune have expanded their non-exclusive licence agreement of 2001 to include additional target antigens
- 09 Jul 2004 Preclinical trials in Cancer in Denmark (unspecified route)